Robbins Umeda LLP has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by members of the Board of Directors of Somanetics Corporation ("Somanetics" or the "Company") (NASDAQ: SMTS) in connection with their actions in causing Somanetics to enter into a definitive merger agreement to be acquired by Covidien plc ("Covidien") (NYSE: COV). If the transaction is completed, Somanetics shareholders will receive $25.00 in cash for each share of Somanetics common stock they hold. The transaction, which will take the form of an all-cash tender offer by a wholly-owned subsidiary of Covidien, followed by a second step merger, is expected to be completed by July 31, 2010.

Robbins Umeda LLP's investigation concerns whether the Board of Directors of Somanetics undertook a fair process to obtain fair consideration for all shareholders of Somanetics. Additionally, our investigation concerns whether the Company's Board of Directors breached their fiduciary duties to Somanetics shareholders by failing to adequately shop the Company before entering into the transaction with Covidien.

If you are a shareholder of Somanetics, plan to continue to hold your shares, and would like more information about your rights as a shareholder, please contact attorney Gregory E. Del Gaizo at 800-350-6003 or by e-mail at info@robbinsumeda.com.

Robbins Umeda LLP is a California-based law firm with significant experience representing investors in merger-related shareholder class actions, shareholder derivative actions, and securities fraud class actions. For more information about the firm, please go to http://www.robbinsumeda.com.

Advertisement

Robbins Umeda LLP
Gregory E. Del Gaizo, 800-350-6003
info@robbinsumeda.com